Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423249 · ClinicalTrials.gov registry record · NA
Treatment of Non-Anemic Iron Deficiency in Pregnancy
A NA study, sponsored by Stony Brook University.
- Completed
- Registry status
- NA
- Development phase
- 150
- Enrollment target
NCT05423249: Completed NA study, sponsored by Stony Brook University.
NCT05423249 is a NA study that has completed, run by Stony Brook University. The registered enrollment target is 150 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05423249, a NA study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
Study Summary
The objective is to investigate the treatment of non-anemic iron deficiency (NAID) and the impact on development of anemia later in pregnancy. Anemia in the third trimester has been identified as a risk factor for maternal and fetal morbidity that might lead to mortality. Due to the high incidence of NAID in pregnancy, there is an opportunity for early screening and treatment to decrease progression to anemia. The primary aim of this study is to establish if treatment of NAID will result in higher third trimester hemoglobin values and decrease incidence of anemia at term.
Primary Outcome
hemoglobin value \<11 mg/dL
Interventions
- DRUG Placebo
- DRUG Ferrous sulfate
- DRUG Docusate Sodium
- DRUG Prenatal
- DRUG Ascorbic Acid 500Mg Tab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2024-11-15 |
| Phase | NA |
What the finished NCT05423249 record still lists
NCT05423249 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05423249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05423249 about?
NCT05423249 is a clinical study titled "Treatment of Non-Anemic Iron Deficiency in Pregnancy". The objective is to investigate the treatment of non-anemic iron deficiency (NAID) and the impact on development of anemia later in pregnancy. Anemia in the third trimester has been identified as a risk factor for maternal and fetal morbidity that might lead to mortality. Due to the high incidence o...
What is the current status of trial NCT05423249?
This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2022-08-12. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT05423249?
The interventions under investigation include: Placebo (DRUG), Ferrous sulfate (DRUG), Docusate Sodium (DRUG), Prenatal (DRUG), Ascorbic Acid 500Mg Tab (DRUG).
Who is sponsoring clinical trial NCT05423249?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05423249's enrollment target sits among peer trials
150 661st of 2000 higher than 1,299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI